{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-23-000071","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.720457+00:00","generated_at":"2026-06-08T22:29:10.212855+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio reports ELI-002 Phase 1 data: 87% T cell response, 86% reduced relapse risk; new preclinical data","bullets":["ELI-002 Phase 1: 87% (20/23) of patients had direct ex vivo mKRAS-specific T cell responses; 100% in vitro.","T cell response strength correlated with 86% reduced risk of relapse and death in pancreatic/colorectal cancer.","In 4 patients assessed post-boost, 100% maintained elevated T cell responses, 75% increased further.","ELI-007 and ELI-008 preclinical: >10-500-fold higher T cell responses vs. conventional comparators in mice.","Data presented at SITC 2023; supports lymph node-targeting AMP platform for solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-23-000071","json":"https://secwatch.observer/filing/0001601485-23-000071.json","markdown":"https://secwatch.observer/filing/0001601485-23-000071.md","text":"https://secwatch.observer/filing/0001601485-23-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000071/0001601485-23-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000071/angn-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:29:10.212855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}